The proxy contest vote on July 28 is the key near-term catalyst. If management wins, the stock may stabilize around its cash value (~$2.40/share implied by activist's bid). If activists win board seats, a sale process or strategic review is likely, potentially unlocking value above current levels. Monitor institutional shareholder voting patterns and any further activist filings ahead of the meeting.
Price Chart
Executive Summary
Seer, Inc. filed a DEFA14A soliciting support for its seven director nominees at the July 28, 2026 annual meeting, opposing activist investors Bradley Radoff and Michael Torok who seek to replace three directors and push for a sale. Management argues the activists' three unsolicited acquisition proposals were below the company's cash value and that Seer's strategy to build the proteomics market will create long-term value. The filing is part of an escalating proxy contest with the annual meeting vote as the key catalyst.
Key Financial Metrics
Key Facts
- Annual meeting scheduled for July 28, 2026; stockholders to vote on election of seven directors, ratification of auditor, say-on-pay, and ratification of Tax Benefit Preservation Plan.
- Activist investors Bradley Radoff and Michael Torok (7.8% owner) submitted three unsolicited acquisition proposals, the latest at $2.40/share plus CVR, which the board rejected.
- Management claims activists' three nominees lack proteomics or life sciences platform operating experience.
- Seer reports installed base expanded 67% over the past year, consumable kit sample volumes growing 69%, and Q1 2026 operating expenses of $18.2M vs $22.8M in Q1 2025.
- Since 2024, Seer repurchased ~13.2M shares at VWAP $1.86 (~$24.5M deployed), reducing net diluted shares by ~15%, with a new $25M buyback announced in February 2026.
- Board unanimously recommends voting FOR all seven management nominees on the BLUE proxy card.
Financial Impact
Q1 2026 operating expenses $18.2M vs $22.8M in Q1 2025; ~$24.5M deployed in share repurchases since 2024; new $25M buyback announced February 2026.
Risk Factors
- Activists may win board seats, leading to a sale process at a price below cash value or a disruptive strategic shift.
- Revenue decline of 34% YoY in Q1 2026 to $2.8M with $15.7M cash burn suggests ongoing operational challenges.
- Stock down ~97% since IPO with cumulative losses >$465M, indicating severe value destruction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-271229 |
| Document: 0001193125-26-271229-index-headers.html | 0001193125-26-271229 |
| Document: 0001193125-26-271229-index.html | 0001193125-26-271229 |
| Document: 0001193125-26-271229.txt | 0001193125-26-271229 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Press Release | $1.97 | awaiting T+20 | — | $1.98 (+0.51%) |
Oct 15, 2026 12d ago | ITC Section 337 | $2.03 | awaiting T+20 | — | $1.98 (−2.46%) |
Oct 8, 2026 18d ago | 3 | $2.19 | awaiting T+20 | — | $1.98 (−9.59%) |
Sep 21, 2026 5w ago | Press Release | $1.86 $2.02 | ▲ +8.60% | ▲ +9.51% | $1.98 (+6.45%) |
Jul 31, 2026 12w ago | 8-K | $2.22 $1.98 | ▼ −10.81% | ▼ −13.80% | $1.98 (−10.81%) |
Jul 28, 2026 12w ago | Press Release | $2.08 $2.02 | ▲ +2.88% | ▲ +7.90% | $1.98 (+4.81%) |
Jul 28, 2026 12w ago | DFAN14A | $2.14 $2.04 | ▼ −4.67% | ▼ −8.05% | $1.98 (−7.48%) |
Jul 20, 2026 14w ago | DEFA14A | $2.04 $2.03 | ▼ −0.49% | ▼ −4.61% | $1.98 (−2.94%) |
Jul 20, 2026 14w ago | Press Release | $2.04 $2.03 | ▼ −0.49% | ▼ −4.61% | $1.98 (−2.94%) |
Jul 8, 2026 15w ago | DEFA14A | $2.18 $2.19 | ▲ +0.46% | ▼ −2.81% | $1.98 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers